KM Biologics Moves Up COVID-19 Vaccine Target, Aims for Rollout in FY2022

KM Biologics said on September 21 that its COVID-19 vaccine yielded positive safety and efficacy data in a Japan PI/II study, prompting it to move up its rollout target by one year to “within FY2022.” The Meiji group company started...read more